Top Pharmaceutical Drugs For 2018

As 2018 begins to take shape, you’ll be seeing a lot of articles that will detail future healthcare trends. Whether it’s a new technology emerging this year, or a new change to the healthcare landscape, many are doing their best to look ahead to the future and decipher what 2018 will bring. One aspect that many aren’t talking about, however, is the top pharmaceutical drugs for 2018 that will emerge. As scientists are hard at work creating new medications, many will have a huge impact on the healthcare industry. At least nine new drugs are expected to launch this year that have the potential for sales to top $1 billion by 2022, according to market research firm EvaluatePharma. Below are just a few pharmaceutical drugs that will be, or are expected to be, released in 2018.

top pharmaceutical drugs for 2018

Top Pharmaceutical Drugs For 2018


This iss easily the most talked about drug to hit the market in 2018. The drug combination designed by Gilead Sciences could change the way we treat HIV. The drug should be the latest in a string of blockbuster HIV drugs developed by Gilead. However, the company’s CEO, John Milligan, thinks that it will be its best ever. Milligan stated in November that the Bictegravir/F/TAF combo will become “the most important product out there” in the HIV market. It’s no wonder that many view this new drug as the top dog when it comes to HIV medication. As for top pharmaceutical drugs in 2018, many experts predict that sales of this drug could surpass $5 billion dollars by 2022.


Another one of the top pharmaceutical drugs for 2018 is a major step in the treatment of breast cancer. It belongs to CDK4/6 inhibitors which have been shown to have the most positive effect on metastatic breast cancer, specifically in HER2+ breast cancers. Abemaciclib is armed with certain advantages over its rivals, as it can be dosed continuously. This means that it can put up a continuous front against cancer cells. The clinical studies results have put Abemaciclib roughly on par with its competitors in the first-line setting. In July 2017, the U.S. Food and Drug Administration (FDA) granted Abemaciclib a Priority Review tag, both as a potential monotherapy and combination therapy. Abemaciclib is estimated to enter the market in 2018 and capture a significant market share in this space. Sales are expected to reach $1,792 million in 2022.


Better known as Ozempic, this drug is supposed to not only combat diabetes, but it’s also supposed to help with the weight loss as well. Many know that diabetes and obesity can often go hand in hand, which makes this one of the top pharmaceutical drugs for 2018. Ozempic is a longer-acting version of Novo Nordisk’s enormously successful diabetes drug, Victoza. Victoza must be taken once daily, while Ozempic only has to be taken once per week.

That makes this drug a clear and present threat to a whole slate of drugs on the market, none of which are doing very well.


Incyte’s Epacadostat is probably the most ambitious and most eagerly anticipated cancer immunotherapy to watch this year. EvaluatePharma projects 2022 Epacodostat sales of close to $2 billion.  This first line treatment is used in combination with Merck’s Keytruda. Studies have shown that 56 percent of melanoma patients treated with the combination responded to the therapy for a median 45 weeks. This immunotherapy will boost the immune system by creating more blood cells designed to attack the cancer head-on. Their cancer also didn’t progress for a median 12.4 months. The FDA probably won’t approve the drug until late in the year, given the hurdles still facing Incyte. It’s no surprise that the FDA monitors drugs like these very closely, so it’s hard to project when and how successful it will be. However, if Incyte is able to pass all necessary hurdles, it will be a game changer.

As always, if you want to work closely with these drugs when they hit the market, check out our pharmacy jobs we have listed!

Author: Troy Diffenderfer

Share This Post On

Submit a Comment

Your email address will not be published. Required fields are marked *